MAGEC1 (MAGE Family Member C1)

Additionally, methylation patterns of AR co-regulators located on the X chromosome suggest epigenetic regulation of AR signaling in gliomas. The findings reveal distinct AR pathway activation patterns in adult-type diffuse gliomas, particularly IDH-wildtype GBMs, suggesting that further exploration of antiandrogen therapies is warranted.

The allelic OR for the dominant allele was 1.08 (0.55-2.11), which is nonsignificant (p = 0.83). The present study suggests that the rs176036 variant does not confer any increased risk of ovarian cancer among population of Jammu and Kashmir.

Our data showed the predictive value of peri-ASCT frontline treatment. A 2-log decrease of MAGE-C1/CT7 post-induction cycle 2 compared to baseline correlated with a negative peri-ASCT MAGE-C1/CT7 status, providing an earlier prognostic marker of treatment response.

These results demonstrate that MAGE-C genes are viable prospective biomarkers of CC controlled by hypomethylating drugs, consequently offering a possible treatment target for CC in a specific population.

Structural analysis of the interaction between MAGE-A3 and Kap1 gives insight into the biochemical activity and substrate specificity and suggests novel pharmacologic strategies to inhibit them. These studies demonstrating MAGE-A3 oncogenic functions suggest that it may also be a suitable target for small molecule inhibition in multiple myeloma that may be broadly applicable to other cancers that express it.

These results align with the limited literature, which suggests a correlation between MAGE expression and older age and HBV infection. Consequently, our study suggests that MAGE-C1 and MAGE-C2 are promising novel biomarkers for prognosis and potential therapeutic targets in HCC.

The CCT4 up-regulation and PRAME mutations were correlated with a good prognosis for ovarian cancer, while higher levels of GAGE2A and CT45A1 mRNAs were correlated with a poor prognosis for ovarian cancer patients. Thus, GAGE2, CT45, CCT4, and PRAME cancer/testis antigens can be considered as potential prognostic markers for ovarian tumors, and GAGE2, CCT4, and PRAME were revealed to be correlated with the prognosis for ovarian cancer patients for the first time.

Chemical complementarity scores for IGL CDR3-MAGEC1 represented a gender bias, with an overrepresentation of males among the higher IGL-CDR3-CTA complementarity scores that were in turn associated with better DFS (logrank p < 0.065). Overall, this study pointed towards potential biomarkers for prognoses that, in some cases are likely gender-specific; and towards biomarkers for guiding therapy, e.g., IGL-based opportunities for antigen targeting in the lung cancer setting.

Our data showed the independent predictive value of peri-ASCT MAGE-C1/CT7 status on PFS in MM patients receiving novel agents and ASCT as frontline treatment. A 2-log decrease of MAGE-C1/CT7 post-induction cycle 2 correlated with peri-ASCT MAGE-C1/CT7-- status, which provided an earlier prognostic marker during treatment.

While this aggressive subset is small, it is of particular therapeutic interest given the availability of EZH2 inhibitors and because overexpressed CTAs may also make it a candidate for immunotherapy. Legal entity responsible for the study The authors.

P1, N=28, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Jun 2022 | Trial primary completion date: Nov 2023 --> Jun 2022